AM ResearchMedical AM

UNSW researchers develop device capable of 3D printing living cells onto internal organs

The prototype, known as F3DB, has the potential to be used as an all-in-one endoscopic surgical tool

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Engineers from the University of New South Wales (UNSW), Sydney, have developed a miniature and flexible soft robotic arm that could be used to 3D print biomaterial directly onto organs inside a person’s body. The new research from UNSW Medical Robotics Lab, led by Dr. Thanh Nho Do and his Ph.D. student, Mai Thanh Thai, in collaboration with other researchers from UNSW including Scientia Professor Nigel Lovell, Dr. Hoang-Phuong Phan, and Associate Professor Jelena Rnjak-Kovacina, is detailed in a paper published in Advanced Science.

Their work has resulted in a tiny flexible 3D bioprinter that has the ability to be inserted into the body just like an endoscope, and directly deliver multilayered biomaterials onto the surface of internal organs and tissues.

The proof-of-concept device, known as F3DB, features a highly maneuverable swivel head that ‘prints’ the bioink, attached to the end of a long and flexible snake-like robotic arm, all of which is controlled externally.

The research team says that, with further development, and potentially within five to seven years, the technology could be used by medical professionals to access hard-to-reach areas inside the body via small skin incisions or natural orifices.

Dr. Do and his team have tested their device inside an artificial colon, and have 3D printed a variety of materials with different shapes on the surface of a pig’s kidney.

“Existing 3D bioprinting techniques require biomaterials to be made outside the body and implanting that into a person would usually require large open-field open surgery which increases infection risks,” said Dr. Do, a Scientia Senior Lecturer at UNSW’s Graduate School of Biomedical Engineering (GSBmE) and Tyree Foundation Institute of Health Engineering (IHealthE).

“Our flexible 3D bioprinter means biomaterials can be directly delivered into the target tissue or organs with a minimally invasive approach… This system offers the potential for the precise reconstruction of three-dimensional wounds inside the body, such as gastric wall injuries or damage and disease inside the colon… Our prototype is able to 3D print multilayered biomaterials of different sizes and shape through confined and hard-to-reach areas, thanks to its flexible body,” continued Dr. Do. “Our approach also addresses significant limitations in existing 3D bioprinters such as surface mismatches between 3D printed biomaterials and target tissues/organs as well as structural damage during manual handling, transferring, and transportation process.”

“Currently, there are no commercially available devices that can perform in situ 3D bioprinting on internal tissues/organs distanced from the skin surface. Some other proof-of-concept devices have been presented, but they are much more rigid and tricky to use in complex and confined spaces inside the body,” added Scientia Professor Nigel Lovell, Head of the GSBmE and Director of the IHealthE.

The smallest F3DB prototype produced by the team at UNSW has a similar diameter to commercial therapeutic endoscopes (approximately 11-13mm), which is small enough to be inserted into a human gastrointestinal tract. However, the researchers say it could easily be scaled even smaller for future medical uses.

Soft robotics

The device features a three-axis printing head directly mounted onto the tip of a soft robotic arm. This printing head, which consists of soft artificial muscles that allow it to move in three directions, works very similarly to conventional desktop 3D printers. The soft robotic arm can bend and twist due to hydraulics and can be fabricated at any length required. Its stiffness can be finely tuned using different types of elastic tubes and fabrics.

The printing nozzle can be programmed to print pre-determined shapes, or operated manually where more complex or undetermined bioprinting is required. In addition to this, the team utilized a machine learning-based controller which can aid the printing process.

To further demonstrate the feasibility of the technology, the UNSW team tested the cell viability of living biomaterial after being printed via their system. Experiments showed the cells were not affected by the process, with the majority of the cells observed to be alive post-printing. The cells then continued to grow for the next seven days, with four times as many cells observed one week after printing.

An all-in-one endoscopic surgical tool

The research team also demonstrated how the F3DB could potentially be used as an all-in-one endoscopic surgical tool to perform a range of functions. They say this could be especially important in surgery to remove certain cancers, especially colorectal cancer, via a process known as endoscopic submucosal dissection (ESD).

Worldwide, colorectal cancer is the third most common cause of cancer death, but early removal of colorectal neoplasia leads to an increase of at least 90% in the patient’s five-year survival rate.

The nozzle of the F3DB printing head can be used as a type of electric scalpel to first mark and then cut away cancerous lesions.

Water can also be directed through the nozzle to simultaneously clean any blood and excess tissue from the site, while faster healing can be promoted by the immediate 3D printing of biomaterial directly while the robotic arm is still in place.

The ability to carry out such multi-functional procedures was demonstrated on a pig’s intestine and the researchers say the results show that the F3DB is a promising candidate for the future development of an all-in-one endoscopic surgical tool.

“Compared to the existing endoscopic surgical tools, the developed F3DB was designed as an all-in-one endoscopic tool that avoids the use of changeable tools which are normally associated with longer procedural time and infection risks,” said Mai Thanh Thai.

The next stage of development for the system, which has been granted a provisional patent, is in vivo testing on living animals to demonstrate its practical use. The researchers also plan to implement additional features, such as an integrated camera and real-time scanning system which would reconstruct the 3D tomography of the moving tissue inside the body.

Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...

Edward Wakefield

Edward is a freelance writer and additive manufacturing enthusiast looking to make AM more accessible and understandable.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services


Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.